- Home
- HQL vs LRMR Comparison
HQL vs LRMR Comparison
Compare HQL & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HQL | LRMR |
|---|---|---|
| Founded | 1992 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 510.2M | 332.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | HQL | LRMR |
|---|---|---|
| Price | $17.12 | $3.87 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $16.71 |
| AVG Volume (30 Days) | 120.9K | ★ 1.5M |
| Earning Date | 01-01-0001 | 11-05-2025 |
| Dividend Yield | ★ 11.56% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.79 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $17.08 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.34 | $1.61 |
| 52 Week High | $14.37 | $5.37 |
Technical Indicators
Market Signals| Indicator | HQL | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 51.93 | 53.09 |
| Support Level | $16.55 | $3.34 |
| Resistance Level | $17.25 | $4.05 |
| Average True Range (ATR) | 0.29 | 0.28 |
| MACD | -0.04 | 0.02 |
| Stochastic Oscillator | 61.76 | 64.81 |
Price Performance
Historical ComparisonAbout HQL abrdn Life Sciences Investors Shares of Beneficial Interest
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mostly in securities of Life Sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser, abrdn Inc to have potential for above-average growth.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.